AbbVie (ABBV) Declares $0.42 Quarterly Dividend; 2.8% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
FDA Votes to Revise Current Indications for Testosterone Therapy
September 17, 2014 4:35 PM EDTAn FDA advisory panel voted 20-1 to revise approved indications for prescribing testosterone therapies.
Stocks on watch include Repros Therapeutics (NASDAQ: RPRX), Auxilium Pharma (NASDAQ: AUXL), Endo Int'l (NASDAQ: ENDP), Lipocine (NASDAQ: LPCN), AbbVie (NYSE: ABBV), and Lilly & Co. (NYSE: LLY).
